Promega signs license agreement with Broad Institute to access CRISPR-Cas9 technology

Promega Corporation announced today it has signed a non-exclusive license agreement with the Broad Institute of MIT and Harvard to sell tools and reagents for CRISPR-Cas9 gene editing, providing scientists new tools for interrogating endogenous biology. Under the agreement, Promega will combine CRISPR-Cas9 technology with its products that knock-in Promega genetic reporters to the genomes of any cell or cell line, enabling customers to explore endogenous biology at physiologically relevant expression levels.

The combination of CRISPR-Cas9 and Promega gene reporters have proven powerful in understanding critical areas of biology. A paper in the journal ACS Chemical Biology explains how the Promega HiBiT Protein Tagging System can be combined with CRISPR-Cas9-mediated gene editing to tag endogenous proteins and simplify their study under natural expression conditions. Another paper also in ACS Chemical Biology explains a strategy for monitoring PROTAC-mediated degradation of endogenously tagged HiBiT-BET family members in live cells.

With this combination of CRISPR and our most advanced reporter technologies like HiBiT, we are able to look at the dynamics of endogenous proteins in real time with unprecedented ease and sensitivity."

Thomas Machleidt, Senior Research Scientist, Promega.

Promega currently offers a number of ways scientists can leverage high power reporters with CRISPR-Cas9 technology, including services to create custom assays or immediate availability of basic reporter tools for labs to configure with CRISPR gene editing.